Enveda Biosciences is a biotechnology company engineering new drugs from plants.
Enveda Biosciences is a biotechnology company engineering new drugs from plants.
Drug Discovery📍 Boulder, COFounded 2019
Current Valuation
$1.2B
as of 2025-Q3
UNICORN
QL Price
$1.2B
0% vs last round
QuantLogix's current estimate for Enveda Biosciences, published 2026-09-27 — in line with the last disclosed round of $1.2B (2025-Q3).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$1.2B
2025-Q3
weight 0.5
How this price has held up
No round has priced for Enveda Biosciences since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Enveda Biosciences, 2026-09-27 (0433ece8ce2b3cf2).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Enveda Biosciences going public?
No. Enveda Biosciences is private and has not filed to go public. There is no S-1 on file.
What is Enveda Biosciences' valuation in 2026?
Enveda Biosciences is valued at $1.2B as of 2025-Q3, set by its Series D ($150M, Sep 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Enveda Biosciences filed an S-1?
No public S-1 is on file for Enveda Biosciences.
How much has Enveda Biosciences raised?
Enveda Biosciences has raised $529.98M in total, most recently a Series D of $150M in Sep 2025.
Is Enveda Biosciences publicly traded — can you buy Enveda Biosciences stock?
No. Enveda Biosciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Enveda Biosciences on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2019
HQ
Boulder, CO
Employees
325
Total Raised
$529.98M
Last Round
Series D — $150M (Sep 2025)
IPO Status
private
Fundraising Status
Series D · $150M · 1y ago
privateTotal raised $529.98M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$150M
Sep 2025
—
$1.2B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Enveda Biosciences — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
Hiring trend
▲ Hiring uptrend
+100% vs 2026-08
Open roles
8
via lever
Product-build share
63%
engineering, research, product, design
Trajectory
expanding
product-led hiring — 63% of open roles build product; the rest are go-to-market and G&A.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Scientist, Invivo PharmacologySenior Principal Scientist, Medicinal ChemistrySenior Research Associate, Invivo PharmacologySr. Clinical Development DirectorSr. Software Engineer, Lab SciencesAssoc. Director, Medicinal Chemistry
Counted from Enveda Biosciences's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
PharmaceuticalBiotechnologyTherapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q3. Refreshed quarterly.